Oregon Public Employees Retirement Fund Acquires New Position in Meridian Bioscience, Inc. (VIVO)

Oregon Public Employees Retirement Fund acquired a new stake in shares of Meridian Bioscience, Inc. (NASDAQ:VIVO) during the fourth quarter, HoldingsChannel reports. The fund acquired 16,126 shares of the company’s stock, valued at approximately $280,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of VIVO. BlackRock Inc. lifted its position in shares of Meridian Bioscience by 5.6% in the 3rd quarter. BlackRock Inc. now owns 6,228,616 shares of the company’s stock worth $92,806,000 after buying an additional 327,584 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Meridian Bioscience by 2.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,347,959 shares of the company’s stock worth $64,784,000 after buying an additional 94,180 shares during the last quarter. Vanguard Group Inc lifted its position in shares of Meridian Bioscience by 2.2% in the 3rd quarter. Vanguard Group Inc now owns 4,347,959 shares of the company’s stock worth $64,784,000 after buying an additional 94,180 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Meridian Bioscience by 6.5% in the 3rd quarter. Renaissance Technologies LLC now owns 2,801,208 shares of the company’s stock worth $41,738,000 after buying an additional 169,932 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Meridian Bioscience by 3.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,886,692 shares of the company’s stock worth $28,112,000 after buying an additional 58,358 shares during the last quarter. Hedge funds and other institutional investors own 90.14% of the company’s stock.

VIVO has been the topic of a number of recent research reports. BidaskClub downgraded shares of Meridian Bioscience from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 15th. ValuEngine upgraded shares of Meridian Bioscience from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Finally, Zacks Investment Research downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating and set a $19.00 price target on the stock. in a research report on Saturday, January 19th.



Meridian Bioscience stock opened at $16.65 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.72 and a current ratio of 6.75. Meridian Bioscience, Inc. has a 1 year low of $13.75 and a 1 year high of $19.84. The stock has a market capitalization of $710.84 million, a PE ratio of 22.50 and a beta of 0.49.

Meridian Bioscience (NASDAQ:VIVO) last posted its quarterly earnings results on Thursday, January 24th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.18 by $0.02. Meridian Bioscience had a net margin of 12.06% and a return on equity of 19.17%. The company had revenue of $51.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same period last year, the firm posted $0.15 EPS. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. On average, research analysts expect that Meridian Bioscience, Inc. will post 0.75 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, February 14th. Shareholders of record on Monday, February 4th were paid a dividend of $0.125 per share. The ex-dividend date of this dividend was Friday, February 1st. This represents a $0.50 annualized dividend and a yield of 3.00%. Meridian Bioscience’s payout ratio is 67.57%.

TRADEMARK VIOLATION WARNING: “Oregon Public Employees Retirement Fund Acquires New Position in Meridian Bioscience, Inc. (VIVO)” was published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://dakotafinancialnews.com/2019/03/15/oregon-public-employees-retirement-fund-acquires-new-position-in-meridian-bioscience-inc-vivo.html.

About Meridian Bioscience

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience, Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply